ArticleClinical and translational medicine2025

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Ksenija Nesic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.